143 related articles for article (PubMed ID: 33040061)
1. Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry.
Zinzani PL; Bregni M; Spione M; Mitterer M; Musuraca G; Bugli A; Piazza F; Pinto A
Acta Haematol; 2021; 144(3):259-263. PubMed ID: 33040061
[TBL] [Abstract][Full Text] [Related]
2. Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
Eyre TA; Linton KM; Rohman P; Kothari J; Cwynarski K; Ardeshna K; Bailey C; Osborne WL; Rowntree C; Eden D; Shankara P; Eyre DW; Jasani P; Chaidos A; Collins GP; Hatton CS
Br J Haematol; 2016 Jun; 173(6):896-904. PubMed ID: 26956150
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
Sancho JM; Navarro B; Soler Campos JA; de Oteyza JP; de Barrenetxea Lekue C; Bregni M; Grasso Cicala S; Spione M; Mombiedro C; Soler B; Zinzani PL
Eur J Haematol; 2020 May; 104(5):499-508. PubMed ID: 31997425
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.
Herbrecht R; Cernohous P; Engert A; Le Gouill S; Macdonald D; Machida C; Myint H; Saleh A; Singer J; Wilhelm M; van der Jagt R
Ann Oncol; 2013 Oct; 24(10):2618-2623. PubMed ID: 23946328
[TBL] [Abstract][Full Text] [Related]
5. Pixantrone: novel mode of action and clinical readouts.
Minotti G; Han H; Cattan V; Egorov A; Bertoni F
Expert Rev Hematol; 2018 Jul; 11(7):587-596. PubMed ID: 29912583
[TBL] [Abstract][Full Text] [Related]
6. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
[TBL] [Abstract][Full Text] [Related]
7. Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma network).
Cencini E; Mecacci B; Rocco M; Innocenti F; Ghio F; Puccini B; Della Seta R; Simonetti F; Mannelli L; Cuccaro A; Bocchia M; Fabbri A
Eur J Haematol; 2022 May; 108(5):383-390. PubMed ID: 35051301
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone.
Cencini E; Rocco M; Ghio F; Simonetti F; Cuccaro A; De Marco F; Consoli C; Bocchia M; Fabbri A
Eur J Haematol; 2023 Aug; 111(2):247-253. PubMed ID: 37161912
[TBL] [Abstract][Full Text] [Related]
9. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Hübel K
Expert Opin Pharmacother; 2018 Nov; 19(16):1829-1834. PubMed ID: 30269614
[TBL] [Abstract][Full Text] [Related]
11. Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.
El-Helw LM; Hancock BW
Expert Opin Investig Drugs; 2007 Oct; 16(10):1683-91. PubMed ID: 17922631
[TBL] [Abstract][Full Text] [Related]
12. Pixantrone maleate for non-Hodgkin's lymphoma.
Mukherji D; Pettengell R
Drugs Today (Barc); 2009 Nov; 45(11):797-805. PubMed ID: 20126672
[TBL] [Abstract][Full Text] [Related]
13. Pixantrone: merging safety with efficacy.
Papadatos-Pastos D; Pettengell R
Expert Rev Hematol; 2013 Feb; 6(1):25-33. PubMed ID: 23373776
[TBL] [Abstract][Full Text] [Related]
14. Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.
Zinzani PL; Corradini P; Martelli M; Minotti G; Oliva S; Spina M; Barosi G; Tura S
Eur J Haematol; 2016 Dec; 97(6):554-561. PubMed ID: 27124765
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.
Broccoli A; Casadei B; Chiappella A; Visco C; Tani M; Cascavilla N; Conconi A; Balzarotti M; Cox MC; Marino D; Goldaniga MC; Marasca R; Tecchio C; Patti C; Musuraca G; Devizzi L; Monaco F; Romano A; Fama A; Zancanella M; Paolini R; Rigacci L; Castellino C; Gaudio F; Argnani L; Zinzani PL
Oncologist; 2019 Sep; 24(9):1246-1252. PubMed ID: 30940746
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Hess G; Hüttmann A; Witzens-Harig M; Dreyling MH; Keller U; Marks R; Ernst T; Pott C; Viardot A; Frontzek F; Trautmann M; Ruckes C; Deuster O; Rosenwald A; Theobald M; Lenz G
Br J Haematol; 2022 Aug; 198(3):482-491. PubMed ID: 35362552
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
18. NICE guidance on pixantrone monotherapy for multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
Landells LJ; Prescott C; Hay N; Sutcliffe F; Stevens A
Lancet Oncol; 2014 Apr; 15(4):381-2. PubMed ID: 24818252
[No Abstract] [Full Text] [Related]
19. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
20. Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2016 Aug; 29(8):1270-8. PubMed ID: 27420111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
